Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANDANTE: Rasagiline Add-on in Early Parkinson's Disease
NCT01049984Phase 4Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Dec 2009
- Primary completion
- Oct 2012
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Parkinson's disease (PD) comparing Rasagiline 1 mg with Placebo (2 arms). Primary endpoint: Unified Parkinson's Disease Rating Scale Total Score (Parts I, II, and III) at 18 weeks. Started Dec 2009; status: completed.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01049984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01049984.